A carregar...
Are We Sure that Adjuvant Chemotherapy is the Best Approach for Resectable Pancreatic Cancer? Are We in the Era of Neoadjuvant Treatment? A Review of Current Literature
The outcome of pancreatic cancer is poor, with a 9% 5-year survival rate. Current treatment recommendations in the 10%–20% of patients who present with resectable disease support upfront resection followed by adjuvant therapy. Until now, only early complete surgical (R0) resection and adjuvant chemo...
Na minha lista:
| Publicado no: | J Clin Med |
|---|---|
| Main Authors: | , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
MDPI
2019
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6912693/ https://ncbi.nlm.nih.gov/pubmed/31717439 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/jcm8111922 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|